Literature DB >> 21524870

Magnetic resonance in the era of molecular imaging of cancer.

John C Gore1, H Charles Manning, C Chad Quarles, Kevin W Waddell, Thomas E Yankeelov.   

Abstract

Magnetic resonance imaging (MRI) has played an important role in the diagnosis and management of cancer since it was first developed, but other modalities also continue to advance and provide complementary information on the status of tumors. In the future, there will be a major continuing role for noninvasive imaging in order to obtain information on the location and extent of cancer, as well as assessments of tissue characteristics that can monitor and predict treatment response and guide patient management. Developments are currently being undertaken that aim to provide improved imaging methods for the detection and evaluation of tumors, for identifying important characteristics of tumors such as the expression levels of cell surface receptors that may dictate what types of therapy will be effective and for evaluating their response to treatments. Molecular imaging techniques based mainly on radionuclide imaging can depict numerous, specific, cellular and molecular markers of disease and have unique potential to address important clinical and research challenges. In this review, we consider what continuing and evolving roles will be played by MRI in this era of molecular imaging. We discuss some of the challenges for MRI of detecting imaging agents that report on molecular events, but highlight also the ability of MRI to assess other features such as cell density, blood flow and metabolism which are not specific hallmarks of cancer but which reflect molecular changes. We discuss the future role of MRI in cancer and describe the use of selected quantitative imaging techniques for characterizing tumors that can be translated to clinical applications, particularly in the context of evaluating novel treatments.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524870      PMCID: PMC3285504          DOI: 10.1016/j.mri.2011.02.003

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  93 in total

1.  Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images.

Authors:  D B Vigneron; S J Nelson; J Murphy-Boesch; D A Kelley; H B Kessler; T R Brown; J S Taylor
Journal:  Radiology       Date:  1990-12       Impact factor: 11.105

Review 2.  Chemical exchange saturation transfer contrast agents for magnetic resonance imaging.

Authors:  A Dean Sherry; Mark Woods
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

3.  Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence.

Authors:  Lutz Lüdemann; Daniel Prochnow; Torsten Rohlfing; Tobias Franiel; Carsten Warmuth; Matthias Taupitz; Hagen Rehbein; Dirk Beyersdorff
Journal:  Ann Biomed Eng       Date:  2009-01-24       Impact factor: 3.934

4.  Studies of restricted diffusion in heterogeneous media containing variations in susceptibility.

Authors:  J H Zhong; J C Gore
Journal:  Magn Reson Med       Date:  1991-06       Impact factor: 4.668

5.  Breast cancer: regional blood flow and blood volume measured with magnetic susceptibility-based MR imaging--initial results.

Authors:  Jean-Paul Delille; Priscilla J Slanetz; Eren D Yeh; Daniel B Kopans; Leoncio Garrido
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

6.  Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Authors:  Manickam Muruganandham; Mihaela Lupu; Jonathan P Dyke; Cornelia Matei; Michael Linn; Kathryn Packman; Kenneth Kolinsky; Brian Higgins; Jason A Koutcher
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

7.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.

Authors:  Ferdia A Gallagher; Mikko I Kettunen; De-En Hu; Pernille R Jensen; René In 't Zandt; Magnus Karlsson; Anna Gisselsson; Sarah K Nelson; Timothy H Witney; Sarah E Bohndiek; Georg Hansson; Torben Peitersen; Mathilde H Lerche; Kevin M Brindle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

8.  Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose.

Authors:  R Gruetter; E J Novotny; S D Boulware; G F Mason; D L Rothman; G I Shulman; J W Prichard; R G Shulman
Journal:  J Neurochem       Date:  1994-10       Impact factor: 5.372

9.  Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Authors:  Mark M Moasser; Lisa J Wilmes; Ching Hang Wong; Sheye Aliu; Ka-Loh Li; Donghui Wang; Yun Kit Hom; Byron Hann; Nola M Hylton
Journal:  J Magn Reson Imaging       Date:  2007-12       Impact factor: 4.813

10.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

View more
  30 in total

1.  Manganese-based MRI contrast agents: past, present and future.

Authors:  Dipanjan Pan; Anne H Schmieder; Samuel A Wickline; Gregory M Lanza
Journal:  Tetrahedron       Date:  2011-11-04       Impact factor: 2.457

Review 2.  Magnetic nanoparticles in magnetic resonance imaging and diagnostics.

Authors:  Christine Rümenapp; Bernhard Gleich; Axel Haase
Journal:  Pharm Res       Date:  2012-03-06       Impact factor: 4.200

3.  Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer.

Authors:  Angela M Jarrett; Meghan J Bloom; Wesley Godfrey; Anum K Syed; David A Ekrut; Lauren I Ehrlich; Thomas E Yankeelov; Anna G Sorace
Journal:  Math Med Biol       Date:  2019-09-02       Impact factor: 1.854

4.  Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen.

Authors:  Felix P Kuhn; David W Crook; Caecilia E Mader; Philippe Appenzeller; G K von Schulthess; Daniel T Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-07       Impact factor: 9.236

Review 5.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

6.  PET/MRI and the revolution of the third eye.

Authors:  Luigi Mansi; Andrea Ciarmiello; Vincenzo Cuccurullo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10       Impact factor: 9.236

Review 7.  A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.

Authors:  Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara
Journal:  Ann Biomed Eng       Date:  2013-09-10       Impact factor: 3.934

8.  Analytical methods for characterizing magnetic resonance probes.

Authors:  Lisa M Manus; Renee C Strauch; Andy H Hung; Amanda L Eckermann; Thomas J Meade
Journal:  Anal Chem       Date:  2012-05-23       Impact factor: 6.986

Review 9.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

Review 10.  MR Imaging Biomarkers in Oncology Clinical Trials.

Authors:  Richard G Abramson; Lori R Arlinghaus; Adrienne N Dula; C Chad Quarles; Ashley M Stokes; Jared A Weis; Jennifer G Whisenant; Eduard Y Chekmenev; Igor Zhukov; Jason M Williams; Thomas E Yankeelov
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.